Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa randomized double-blind placebo-controlled study of HY-078020 tablets in chronic spontaneous urticaria
CTR20262028Phase 2Active
- Sponsor
- Hefei Yigong Pharmaceutical
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HY-078020 in chronic idiopathic urticaria (CIU), sponsored by Hefei Yigong Pharmaceutical. Started Jun 2026; status: active.
02
Drugs
HY-078020
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on CTR20262028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262028.